Direct-Acting Antivirals in Treatment-Experienced HCV Patients

[Guest guest]

clinical care options

CME/CE-Certified Module

September 9, 2011

Direct-Acting Antivirals in Treatment-Experienced HCV Patients

In this chapter from CCO's Annual Update 2011, Ira M. son, MD,

reviews the data from povotal studies and discusses optimal use of protease

inhibitor therapy in treatment-experienced individuals with genotype 1 HCV

infection.

Topics covered include:

New Standard of Care in HCV Therapy

Overview of Lessons Learned From Phase II Trials of Boceprevir and Telaprevir

Overview of Phase III Trials of Boceprevir and Telaprevir in

Treatment-Experienced Patients With Genotype 1 HCV

RESPOND-2: Phase III Trial of Boceprevir in Treatment-Experienced Patients With

Genotype 1 HCV

REALIZE: Phase III Trial of Telaprevir in Treatment-Experienced Patient With

Genotype 1 HCV

HCV Drug Resistance in Treatment-Experienced Patients Failing Protease

Inhibitors

Conceptual Approach to Treating Previous Treatment Failures

HIV and Hepatitis C Annual Update 2011

http://clinicaloptions.com/Hepatitis/Annual%20Updates/2011%20Annual%20Update.asp\

x

Hepatitis Slide

Library

Review hundreds

of slidesets featuring

the latest hepatitis

treatment data. Then download PowerPoint files for use in your own

noncommercial talks. Click here to start.

HCV Treatment

FIND THE ANSWERS AT INPRACTICE.COM

Physicians: Jointly sponsored by the Annenberg Center for Health Sciences

at Eisenhower and Clinical Care Options, LLC.

Nurses: Annenberg Center for Health Sciences is accredited as a provider

of continuing nursing education by the American Nurses Credentialing Center's

Commission on Accreditation.

Pharmacists: The Annenberg Center for Health Sciences at Eisenhower is

accredited by the Accreditation Council for Pharmacy Education as a provider of

continuing pharmacy education.

Release date: August 18, 2011

Expiration date: August 17, 2012

Supported by educational grants from Abbott Laboratories, Gilead

Sciences, Merck & Co, Tibotec, and Vertex.

Topics

Fibrosis and Cirrhosis

HIV Coinfection

HBV

Nash, ALD, etc

HCV

Other Hepatitis Viruses

Hepatocellular Carcinoma

Transplantation

Resources

Live Events

Expert Viewpoints

Bookstore

Slideset Downloads

Interactive Tools

Webcasts

Podcasts

Guidelines

Conference Coverage

CME Programs

Slidesets

Cases

Live Events

Bookstore

Resources

Site Map

RSS

Contact Us

Help

Site Requirements

Terms of Use

Privacy Policy

HIVSite Tour

International Editions

To ensure you receive Clinical Care Options educational materials by

email,

please add info@... to your contacts or address book.

Not

a member yet? Click here |

[Guest guest]

clinical care options

CME/CE-Certified Module

September 9, 2011

Direct-Acting Antivirals in Treatment-Experienced HCV Patients

In this chapter from CCO's Annual Update 2011, Ira M. son, MD,

reviews the data from povotal studies and discusses optimal use of protease

inhibitor therapy in treatment-experienced individuals with genotype 1 HCV

infection.

Topics covered include:

New Standard of Care in HCV Therapy

Overview of Lessons Learned From Phase II Trials of Boceprevir and Telaprevir

Overview of Phase III Trials of Boceprevir and Telaprevir in

Treatment-Experienced Patients With Genotype 1 HCV

RESPOND-2: Phase III Trial of Boceprevir in Treatment-Experienced Patients With

Genotype 1 HCV

REALIZE: Phase III Trial of Telaprevir in Treatment-Experienced Patient With

Genotype 1 HCV

HCV Drug Resistance in Treatment-Experienced Patients Failing Protease

Inhibitors

Conceptual Approach to Treating Previous Treatment Failures

HIV and Hepatitis C Annual Update 2011

http://clinicaloptions.com/Hepatitis/Annual%20Updates/2011%20Annual%20Update.asp\

x

Hepatitis Slide

Library

Review hundreds

of slidesets featuring

the latest hepatitis

treatment data. Then download PowerPoint files for use in your own

noncommercial talks. Click here to start.

HCV Treatment

FIND THE ANSWERS AT INPRACTICE.COM

Physicians: Jointly sponsored by the Annenberg Center for Health Sciences

at Eisenhower and Clinical Care Options, LLC.

Nurses: Annenberg Center for Health Sciences is accredited as a provider

of continuing nursing education by the American Nurses Credentialing Center's

Commission on Accreditation.

Pharmacists: The Annenberg Center for Health Sciences at Eisenhower is

accredited by the Accreditation Council for Pharmacy Education as a provider of

continuing pharmacy education.

Release date: August 18, 2011

Expiration date: August 17, 2012

Supported by educational grants from Abbott Laboratories, Gilead

Sciences, Merck & Co, Tibotec, and Vertex.

Topics

Fibrosis and Cirrhosis

HIV Coinfection

HBV

Nash, ALD, etc

HCV

Other Hepatitis Viruses

Hepatocellular Carcinoma

Transplantation

Resources

Live Events

Expert Viewpoints

Bookstore

Slideset Downloads

Interactive Tools

Webcasts

Podcasts

Guidelines

Conference Coverage

CME Programs

Slidesets

Cases

Live Events

Bookstore

Resources

Site Map

RSS

Contact Us

Help

Site Requirements

Terms of Use

Privacy Policy

HIVSite Tour

International Editions

To ensure you receive Clinical Care Options educational materials by

email,

please add info@... to your contacts or address book.

Not

a member yet? Click here |